Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2016-12-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
华泰联合证券有限责任公司关于公司发行股份购买资产暨关联交易之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a major asset restructuring transaction involving the issuance of shares to purchase assets and related party transactions by 嘉事堂药业股份有限公司. It includes detailed financial data, transaction terms, valuation summaries, shareholder structure changes, and regulatory compliance information. The document is comprehensive and exceeds 15,000 characters, indicating it is a full report rather than a brief announcement. The content focuses on a significant corporate transaction involving issuance of shares to purchase assets, which aligns with capital/financing activities. The document is not a general annual report, earnings release, or management discussion, but a specialized advisory report on a capital transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-12-30 Chinese
北京市金杜律师事务所关于公司发行股份购买资产暨关联交易之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm (北京市金杜律师事务所) regarding 嘉事堂药业股份有限公司's issuance of shares to purchase assets and related party transactions. It references Chinese securities laws, the China Securities Regulatory Commission (中国证监会), and Shenzhen Stock Exchange (深交所) regulations. The document includes detailed descriptions of the transaction, parties involved, share issuance details, asset purchase agreements, performance commitments, and audit and asset appraisal reports related to the transaction. The document is lengthy (15,000 characters) and contains substantive content about a share issuance to purchase assets, which is a capital/financing activity. It is not a simple announcement or a report publication notice, nor is it a transcript, management report, or annual/interim report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2016-12-30 Chinese
华泰联合证券有限责任公司关于公司本次交易产业政策和交易类型之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an independent financial advisor's verification opinion regarding a major asset restructuring transaction involving Jia Shi Tang Pharmaceutical Co., Ltd. It references regulatory frameworks such as the Securities Law of the People's Republic of China, the Company Law, and specific guidelines on major asset restructuring and mergers. The content focuses on verifying the transaction type, industry classification, whether it involves share issuance, and compliance with regulatory requirements. It is a detailed advisory opinion related to a capital transaction and restructuring, not a full annual or interim financial report, nor a simple announcement. The document is a formal independent financial advisor's report on a capital/financing transaction involving issuance of shares for asset purchase and related regulatory compliance. Therefore, it fits best under Capital/Financing Update (CAP). The document length (5455 characters) and detailed content support this classification with high confidence.
2016-12-30 Chinese
华泰联合证券有限责任公司关于公司本次发行股份购买资产暨关联交易前12个月内购买、出售资产情况的说明
Capital/Financing Update Classification · 95% confidence The document is a statement from Huatai United Securities regarding the asset purchase and sale activities of Jiashitang Pharmaceutical Co., Ltd. in the 12 months prior to a planned issuance of shares for asset purchase and related party transactions. It details specific asset transactions and clarifies their relation to the current transaction. The document is short (677 characters) and serves as an explanatory note related to a capital transaction rather than a full financial report or detailed filing. It is not an annual or interim report, audit report, or earnings release. It is also not a proxy, voting result, or management change announcement. The content focuses on capital transactions and related disclosures. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-12-30 Chinese
深圳嘉事康元医疗器械有限公司审计报告及财务报表
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements." It includes detailed financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements for the period from January 1, 2014, to September 30, 2016. The document also contains an auditor's opinion and references to Chinese Certified Public Accountant auditing standards. The length is substantial (15,000 characters), and the content includes full financial data and audit opinions, not just an announcement or certification. Therefore, this document is a standalone audit report with financial statements, fitting the category of Audit Report / Information (AR). 9M 2016
2016-12-30 Chinese
上海嘉事明伦医疗器材有限公司审计报告及财务报表
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the period from January 1, 2014 to September 30, 2016. It includes detailed financial statements such as balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The document also contains an auditor's opinion section, responsibilities of management and auditors, and certification by Chinese certified public accountants. The length is substantial (15,000 characters), and the content is the full audit report and financial statements, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. 9M 2016
2016-12-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.